| 2013 | Design of precise third-line therapy for gastric cancer: target or chemotherpy?
| KOREAN JOURNAL OF INTERNAL MEDICINE |
| 2021 | Detection of EGFR-SEPT14 fusion in cell-free DNA of a patient with advanced gastric cancer: A case report
| WORLD JOURNAL OF CLINICAL CASES |
| 2016 | Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer
| CLINICAL CANCER RESEARCH |
| 2007 | Diagnostic application of serum proteomic patterns in gastric cancer patients by ProteinChip surface-enhanced laser desorption/ionization time-of-flight mass spectrometry | INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS |
| 2007 | Docetaxel-Induced Onycholysis: The Role of Subungual Hemorrhage and Suppuration
| YONSEI MEDICAL JOURNAL |
| 1999 | Effects of interleukin-2 transduction on the human hepatoma cell lines using retroviral vector | ONCOLOGY REPORTS |
| 2018 | Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG) | GASTRIC CANCER |
| 2018 | Efficacy of adjuvant chemotherapy for completely resected stage IB non-small cell lung cancer: a retrospective study
| JOURNAL OF THORACIC DISEASE |
| 2017 | Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer | CLINICAL CANCER RESEARCH |
| 2009 | Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group
| JOURNAL OF THORACIC ONCOLOGY |
| 2002 | Evaluation of E1b gene-attenuated replicating adenoviruses for cancer gene therapy
| CANCER GENE THERAPY |
| 2020 | Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
| GASTRIC CANCER |
| 2009 | Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2015 | Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
| CANCER RESEARCH AND TREATMENT |
| 2011 | Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer.
| PLOS ONE |
| 2011 | Gene expression signature-based prognostic risk score in gastric cancer
| CLINICAL CANCER RESEARCH |
| 2023 | Global loss of cellular m6A RNA methylation following infection with different SARS-CoV-2 variants
| GENOME RESEARCH |
| 1997 | High Level of Urokinase-Type Plasminogen Activator Is a New Prognostic Marker in Patients with Gastric Carcinoma | CANCER |
| 2024 | Identification of Potential Genomic Alterations Using Pan-Cancer Cell-Free DNA Next-Generation Sequencing in Patients With Gastric Cancer
| ANNALS OF LABORATORY MEDICINE |
| 2021 | Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight
| VIRUSES-BASEL |
| 2020 | Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial
| EUROPEAN JOURNAL OF CANCER |
| 2013 | Molecular diagnosis for personalized target therapy in gastric cancer
| JOURNAL OF GASTRIC CANCER |
| 2022 | Nanomedicine for glioblastoma: Progress and future prospects | SEMINARS IN CANCER BIOLOGY |
| 2017 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | LANCET |
| 2021 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
| GASTRIC CANCER |
| 2007 | Non-Hodgkin's lymphoma of the sphenoid sinus presenting as isolated oculomotro never palsy
| WORLD JOURNAL OF SURGICAL ONCOLOGY |
| 2002 | Observation of Cabibbo-suppressed and W-exchange Λc+ baryon decays | PHYSICS LETTERS B |
| 2010 | Outcome of adjuvant therapy for gallbladder cancer | ONCOLOGY |
| 1996 | Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical Stain | ONCOLOGY |
| 2016 | Overexpression of Endoplasmic Reticulum Oxidoreductin 1-α (ERO1L) Is Associated with Poor Prognosis of Gastric Cancer
| CANCER RESEARCH AND TREATMENT |
| 2013 | Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2012 | Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2009 | Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. | CHEMOTHERAPY |
| 2003 | Phase II Study of Gemcitabine and Vinorelbine as Second-Line Chemotherapy in Non-Small Cell Lung Cancer
| CANCER RESEARCH AND TREATMENT |
| 2016 | Phase II trial of dacomitinib in patients with HER2-positive gastric cancer | GASTRIC CANCER |
| 2008 | Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. | ANTI-CANCER DRUGS |
| 2006 | Preoperative staging accuracy of multidetector row computed tomography for extrahepatic bile duct carcinoma | JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY |
| 2017 | Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data
| JOURNAL OF GASTRIC CANCER |
| 2011 | Prognostic factors of second and third line chemotherapy using 5-fu with platinum, irinotecan, and taxane for advanced gastric cancer.
| CANCER RESEARCH AND TREATMENT |
| 2017 | Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score | JAMA ONCOLOGY |
| 2014 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | LANCET |
| 2015 | Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 1997 | Relationship between p53 Overexpression and Gastric Cancer Progression | ONCOLOGY |
| 1997 | Retrospective Comparison of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Modified FAM) Combination Chemotherapy Versus Palliative Therapy in Treatment of Advanced Gastric Cancer | American Journal of Clinical Oncology |
| 2008 | Salvage chemotherapy with docetaxel and epirubicin for Advanced/Metastatic gastric cancer | ONCOLOGY |
| 2018 | Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY |
| 2016 | Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2017 | Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2014 | Targeted therapy in gastric cancer: Personalizing cancer treatment based on patient genome
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2012 | Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2012 | Treatment outcome of patients with anaplastic thyroid cancer: a single center experience
| YONSEI MEDICAL JOURNAL |
| 2005 | 간세포암 환자에서 간동맥 화학색전술 후 발생한 급성 간부전의 위험인자
| Korean Journal of Medicine (대한내과학회지) |
| 1996 | 골육종환자에서 다방면 복합요법의 효과 및 P-Glycoprotein 과다발현의 임상적 의의
| Journal of the Korean Cancer Association(대한암학회지) |
| 1995 | 근치적 절제술이 시행된 대장 및 직장암에서 c-erbB-2의 표현과 임상적 의의
| Journal of the Korean Cancer Association(대한암학회지) |
| 1999 | 노령층 비호지킨 림프종 환자의 치료성적 및 예후
| Journal of the Korean Cancer Association (대한암학회지) |
| 2012 | 복강 내에서 발견된 기관지원성낭종 내의 선암 1예
| Korean Journal of Medicine |
| 1997 | 생물학적 치료 목표로서 위암에서 Midkine 발현의 탐색 | Journal of the Korean Cancer Association (대한암학회지) |
| 2013 | 성인에서 천미부 기형종의 선암으로 전환 1예
| Korean Journal of Medicine |
| 1996 | 악성 종양 환자에서 새로운 Anthracycline 유도체: DA-125의 제1상 및 약동학 연구
| Journal of the Korean Cancer Association(대한암학회지) |
| 1996 | 위암에서 침윤과 전이의 새로운 생물학적 표지자로서 urokinase-type plasminogen activator(uPA)의 발현
| Journal of the Korean Cancer Association(대한암학회지) |
